Doximity, Inc. (NYSE:DOCS – Get Free Report) Director Timothy Cabral sold 10,721 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $35.00, for a total value of $375,235.00. Following the sale, the director owned 8,084 shares in the company, valued at $282,940. This trade represents a 57.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Doximity Stock Up 1.6%
Shares of Doximity stock opened at $33.02 on Tuesday. Doximity, Inc. has a twelve month low of $17.15 and a twelve month high of $55.96. The business has a 50-day moving average price of $29.22 and a 200 day moving average price of $25.47. The firm has a market cap of $5.89 billion, a PE ratio of 45.87, a P/E/G ratio of 27.12 and a beta of 1.29.
Doximity (NYSE:DOCS – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.17. The company had revenue of $174.54 million during the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.45 EPS. On average, sell-side analysts expect that Doximity, Inc. will post 0.74 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on DOCS shares. Weiss Ratings raised Doximity from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, October 6th. Wolfe Research upgraded Doximity to an “outperform” rating in a research report on Thursday, August 13th. Wells Fargo & Company lowered shares of Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 price target for the company. in a report on Monday, August 10th. Royal Bank Of Canada upped their price objective on shares of Doximity from $28.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Freedom Capital downgraded shares of Doximity from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Eight research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $30.45.
View Our Latest Analysis on Doximity
Trending Headlines about Doximity
Here are the key news stories impacting Doximity this week:
- Positive Sentiment: Analysts raised Doximity price targets to $40 and $34, and Needham reiterated its Buy rating, signaling continued optimism from some analysts. Read More.; Read More.; Read More..
- Neutral Sentiment: Director Timothy Cabral sold 10,721 shares for about $375,000 under a pre-arranged Rule 10b5-1 plan. The planned nature of the sale may temper its significance, though insider selling can still concern investors. Read More..
- Negative Sentiment: Several law firms publicized a securities class action against Doximity and a November 16 lead-plaintiff deadline. The suit covers investors who bought shares from August 8, 2024, through May 13, 2026, and alleges the company misrepresented or failed to disclose issues involving revenue growth, market share, slowing sales, declining net income, and pharmaceutical customers’ advertising budgets. These are allegations, not established findings; the litigation could add uncertainty and reputational risk. Read More..
Hedge Funds Weigh In On Doximity
Hedge funds have recently made changes to their positions in the company. Signaturefd LLC boosted its position in Doximity by 10.4% during the third quarter. Signaturefd LLC now owns 4,205 shares of the company’s stock worth $119,000 after purchasing an additional 397 shares in the last quarter. Allworth Financial LP grew its holdings in Doximity by 29.3% in the third quarter. Allworth Financial LP now owns 2,642 shares of the company’s stock valued at $75,000 after purchasing an additional 599 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Doximity by 59.9% in the third quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company’s stock valued at $53,000 after buying an additional 695 shares in the last quarter. Apella Capital LLC increased its position in shares of Doximity by 1.4% in the third quarter. Apella Capital LLC now owns 59,488 shares of the company’s stock valued at $1,647,000 after buying an additional 802 shares in the last quarter. Finally, Bessemer Group Inc. increased its position in shares of Doximity by 79.8% in the third quarter. Bessemer Group Inc. now owns 1,910 shares of the company’s stock valued at $54,000 after buying an additional 848 shares in the last quarter. Institutional investors and hedge funds own 87.19% of the company’s stock.
Doximity Company Profile
Doximity, Inc operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals.
The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.
Founded in 2010, Doximity primarily serves the U.S.
Read More
- Five stocks we like better than Doximity
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
